Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well vismodegib works in treating adult patients with
recurrent or refractory medulloblastoma. Vismodegib may slow the growth of tumor cells and
may be an effective treatment for medulloblastoma.